Company Overview - Liquidia Technologies, Inc. (LQDA) shares increased by 13.2% to close at $15.83, with notable trading volume compared to typical sessions, following a 1.1% loss over the past four weeks [1][2] Recent Developments - The U.S. District Court for the District of Columbia dismissed a cross-claim by United Therapeutics challenging Liquidia's amendment to its new drug application for Yutrepia, which now includes treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] Financial Expectations - Liquidia is expected to report a quarterly loss of $0.42 per share, reflecting a year-over-year increase of 22.2%, with revenues projected at $3.31 million, up 11.4% from the previous year [3] - The consensus EPS estimate for Liquidia has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Liquidia Technologies operates within the Zacks Medical - Biomedical and Genetics industry, where CRISPR Therapeutics AG (CRSP) also competes, having closed 1.4% higher at $38.25 and showing a 15.5% return over the past month [4]

Company Overview - Stellus Capital (SCM) shares increased by 7.1% to close at $12.52, following a notable trading volume compared to typical sessions, despite a 15.4% loss over the past four weeks [1] - The stock surge was influenced by a broader market jump, attributed to President Trump's announcement of a 90-day tariff pause for non-retaliating nations, which positively impacted investor sentiment [2] Earnings Expectations - Stellus Capital is expected to report quarterly earnings of $0.37 per share, reflecting a year-over-year decline of 15.9%, with revenues projected at $26.26 million, a 1% increase from the previous year [2] - The consensus EPS estimate for Stellus Capital has been revised 4.6% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Stellus Capital operates within the Zacks Financial - SBIC & Commercial Industry, where another company, WhiteHorse Finance (WHF), saw a 5.4% increase in its stock price, closing at $9.14, despite a -11.7% return over the past month [4] - WhiteHorse's consensus EPS estimate has decreased by 11.1% to $0.33, representing a year-over-year change of -29.8%, and it currently holds a Zacks Rank of 4 (Sell) [5]